COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					1 Months Ended					3 Months Ended		12 Months Ended
	Jul. 05, 2022	May 01, 2022	Oct. 10, 2016	Feb. 10, 2015	Mar. 31, 2023	Jun. 15, 2022	Mar. 23, 2022	Mar. 21, 2022	Jan. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 29, 2021	Aug. 01, 2018	Feb. 28, 2018	Apr. 27, 2017	Oct. 31, 2016	Sep. 25, 2014
Loss Contingencies [Line Items]
Warrants exercisable per share										$ 0.75
Compensation increased		$ 25,000
Cash compensation paid										$ 154,933
Exercise bonus											75.00%
Warrants held by trust owned										3,000,000
Warrants and Rights Outstanding										17,612,151
Debt instrument paid amount									$ 2,665,500
Debt Instrument, Interest Rate During Period								25.00%	25.00%
Principal, interest								$ 666,375	$ 666,375
Aggregate payment	$ 1,999,125
Sale of domain, description							the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.
Loan related to construction															$ 10,010,000
Accrued interest															2,255,802
Total assets										5,414,725	$ 297	$ 6,360,337			0
Total liabilities										6,548,173	10,154,334	7,254,916			10,234,501
Accounts payable and accrued liabilities										549,425	9,939,148	1,360,644			10,009,802
Accounts payable											214,235				212,263
Accrued Liabilities, Current											950				$ 12,436
Gain on legal dissolution of subsidiary										$ 10,234,501
Line of Credit, Current												9,868,495	$ 9,868,495
Weighted average remaining lease term										2 years 3 months 29 days
Discounted rate										10.00%
P A 1 [Member]
Loss Contingencies [Line Items]
Debt Instrument, Debt Default, Amount																				$ 8,137,117
Gain (Loss) on Securitization of Financial Assets						$ 104,725
Pennvest Loan [Member]
Loss Contingencies [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity										$ 7,754,000
Debt Instrument, Annual Principal Payment										5,886,000
Long-Term Debt, Maturity, Year Two										846,000
Long-Term Debt, Maturity, Year Three										873,000
Long-Term Debt, Maturity, Year Four										149,000
Interest Expense, Debt										$ 123,444	246,887	$ 123,444	$ 246,887
Minimum [Member]
Loss Contingencies [Line Items]
Warrants exercisable per share										$ 0.60
Exercise bonus										50.00%
Maximum [Member]
Loss Contingencies [Line Items]
Warrants exercisable per share										$ 1.60
Exercise bonus										90.00%
Years One Through Five [Member] | Pennvest Loan [Member]
Loss Contingencies [Line Items]
Debt Instrument, Interest Rate During Period										2.547%
Years Six Through Maturity [Member] | Pennvest Loan [Member]
Loss Contingencies [Line Items]
Debt Instrument, Interest Rate During Period										3.184%
Smith [Member]
Loss Contingencies [Line Items]
Cash compensation paid										$ 60,000	54,000
President [Member]
Loss Contingencies [Line Items]
Monthly Officers Cash Compensation			$ 18,000
Warrants exercisable per share										$ 0.75
President [Member] | Extension Bonus [Member] | Fy 2016 Extension Agreement [Member]
Loss Contingencies [Line Items]
Deferred Compensation, Maximum Convertible Amount																		$ 300,000	$ 125,000
Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)																		$ 0.75	$ 0.75
President [Member] | Warrants Issused Subscription Receivable [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)														300,000
Warrants exercisable per share										0.60
President [Member] | Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]
Loss Contingencies [Line Items]
Warrants exercisable per share										$ 0.75
Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Monthly Officers Cash Compensation				$ 31,000						$ 25,000
Warrants exercisable per share		$ 1.00
Cash compensation paid										45,500	0
Deferred Compensation, Maximum Convertible Amount										10,000
Exercise bonus		75.00%
Number of shares issued		1,000,000
Cancellation of warrants		700,000
Chief Executive Officer [Member] | Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]
Loss Contingencies [Line Items]
Financing Receivable, after Allowance for Credit Loss, Total										351,812
Repayments of Long-term Debt, Total										$ 75,000	$ 60,000
Chief Executive Officer [Member] | Warrants Issused Subscription Receivable [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										5,565,000
Chief Executive Officer [Member] | Warrants Expiring On December 312025 [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																3,000,000
Bassani [Member]
Loss Contingencies [Line Items]
Salaries and wages																	$ 31,000
Additional paid amount																	$ 2,000
Bassani [Member] | Forecast [Member]
Loss Contingencies [Line Items]
Interest bearing secured promissory note					$ 300,000